Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73590244" target="_blank" >RIV/61989592:15110/18:73590244 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1712126" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1712126</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1712126" target="_blank" >10.1056/NEJMoa1712126</a>
Alternative languages
Result language
angličtina
Original language name
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Original language description
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
NEW ENGLAND JOURNAL OF MEDICINE
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
378
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
1277-1290
UT code for WoS article
000429105700004
EID of the result in the Scopus database
2-s2.0-85045136401